Roche's Xolair Granted FDA Priority Review
By Mauro Orru
Roche Holding's Xolair antibody received priority review treatment from the Food and Drug Administration after a late-stage study yielded positive results that the company said could make Xolair the first medicine to reduce allergic reactions to multiple foods.
The Swiss pharmaceutical company said Tuesday that the FDA should make a decision on approval in the first quarter of the new year, after positive results from a phase 3 study assessing Xolair in patients allergic to peanuts and at least two other common foods.
"Despite the significant and growing health burden from food allergies, treatment advances have been limited," said Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development. "The FDA's priority review designation acknowledges the unmet need for these patients, and we hope to make Xolair available to as many people as possible living with food allergies in the U.S."
Write to Mauro Orru at mauro.orru@wsj.com
(END) Dow Jones Newswires
December 19, 2023 10:12 ET (15:12 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?